Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript
Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
Alvotech NASDAQ: ALVO Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through regulatory review and prepares for a broader launch cycle over the next several years.
Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
Alvotech remains a commercial-stage biosimilar company with real revenue, partners, and a growing global footprint. I believe its main upside potential lies with the resubmission of AVT05 and AVT06 after its recent manufacturing delays in the US. ALVO's valuation has been punished by regulatory setbacks in its manufacturing facilities. So if those concerns are resolved, the stock could quickly re-rate higher.
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Alvotech NASDAQ: ALVO is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York.
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End
Alvotech NASDAQ: ALVO Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June after addressing manufacturing observations that led to complete response letters for pipeline products.
Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.35 per share a year ago.
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers.
Alvotech: Why FDA Delays Don't Break The Bull Case
Alvotech remains my favorite in the biosimilars market, which is expected to reach $151.6 billion by 2033. It already has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. Even though it received three CRLs in Q4, Alvotech expects its revenue to be between $650 million and $700 million in 2026, up 37.2% from 2024.
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
